Polycystic Ovarian Syndrome (PCOS) is one of the most commonly diagnosed hormonal conditions affecting women all over the world. Despite how common it is, the term PCOS did not fully encompass the nature and reality of living and treating this condition. PCOS received an official name change. Let’s talk about it and how this may affect you.
What is the new name and why was it changed?
PCOS is now changed to PMOS – Polyendocrine Metabolic Ovarian Syndrome.
The term “polycystic ovarian syndrome” put the emphasis on having cysts on the ovaries while many people diagnosed with PCOS do not actually have ovarian cysts. Women with PCOS experience symptoms far beyond the ovaries and struggle with not just reproductive but whole body metabolic concerns as well.
For years, women with PCOS have been struggling with weight gain, fatigue, acne and insulin resistance. PMOS highlights that this condition is not purely a condition of cystic ovaries but affects hormones, insulin regulation, metabolism, inflammation, skin health, mood and mental health and cardiovascular risk.
What Does PMOS Mean?
PMOS stands for Polyendocrine Metabolic Ovarian Syndrome, and each part of the name reflects an important aspect of the condition.
Polyendocrine – recognizes that multiple hormone systems are involved, not just reproductive hormones.
Metabolic – highlights the strong connection between PMOS and metabolic health. Many women with PMOS experience insulin resistance, blood sugar dysregulation, cholesterol abnormalities, inflammation, and weight fluctuations.
Ovarian – remains relevant because many women continue to experience irregular cycles, ovulation dysfunction and fertility challenges.
What Symptoms Can PMOS Cause?
PMOS can look very different from person to person. Some individuals struggle with menstrual irregularities, while others notice skin concerns, fatigue, or metabolic symptoms first.
Common symptoms may include irregular or absent periods, acne, excess facial or body hair growth, hair thinning, difficulty losing weight, fatigue, sugar cravings, mood changes, fertility challenges, and insulin resistance.
Why This Name Change Matters
For many women, the previous name minimized the complexity of the condition.
It also shifts the conversation away from viewing the condition as purely reproductive and toward understanding its broader impact on long-term health. Research continues to show that women with PMOS experience some degree of insulin resistance, even if they are not overweight. Over time, unmanaged insulin resistance may increase the risk of diabetes, high cholesterol, fatty liver disease and cardiovascular disease.
This does not mean these outcomes are inevitable. Early support and targeted treatment can make a significant difference.
How PMOS Is Treated
Treatment for PMOS should always be individualized and based on a person’s symptoms, goals, and overall health picture. A naturopathic doctor will look at a whole-body approach to hormone health by looking at the connections between metabolism, digestion, stress, sleep, inflammation, and reproductive function. Treatment may include improving blood sugar regulation, optimizing protein and fibre intake, incorporating movement and strength training, addressing stress and sleep quality, supporting ovulation, and using targeted supplementation where appropriate.
What You Should Know Moving Forward
If you were previously diagnosed with PCOS, your diagnosis has not suddenly changed overnight. PMOS is the updated terminology being adopted to better reflect the condition’s complexity.
During this transition period, you will likely continue hearing both PCOS and PMOS used interchangeably while guidelines, clinics, and educational resources are updated.
If you are looking for support with hormone health, metabolism, or PMOS symptoms, book a discovery call or initial consultation with Dr. Eva to learn more!
References
Teede, H.J., et al. (2023). International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Monash University. https://doi.org/ 10.26180/24003834.v1
Teede, H.J., et al. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. https://doi.org/ 10.1016/S0140-6736(26)00717-8
